SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V}
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JMarcus who wrote (37)1/30/1999 4:01:00 PM
From: BRAVEHEART  Read Replies (2) of 423
 
Hi JMarcus,

SUNP looks interesting. The P-2 study for cancer appears exceptionally short and of unusual dimensions. It sounds more like a P-2A study. One which is searching for potential indications to advance into a P-2B study. Do you know what six solid tumor types are in clinical trials? Do you know the eventual targeted market size ( this is a key consideration )? To date what are the toxicity and side effect issues with DENSPM. Why is it considered a fast-trac P-2 trial? It does appear of a rather short duration. Did the FDA grant this fast trac consideration and why? Were there any results in P-1 or interum P-2 which suggest the product may be adv without P-3 data?

You also mentioned:

"The company's Phase 2 trial of DEHOP for refractory diarrhea in AIDS patients had a recent setback when the FDA asked for a stronger safety profile. DEHOP is both an anti-motility drug and also an anti-secretory drug (by way of contrast, Shaman's competing drug, Provir, is just an anti-secretory drug)."

What were the safety issues? Would you guess SUNP will start over with DEHOP? Or better yet go with DESPM? My guess is this is a market with unmet needs. Was / is Shaman the only other company working on this indication.

I also noted that the number of shares in float is only 100K. Yet there are around 6+ million shares outstanding. Who are the primary shareholders?

PS: Thanks J Marcus. Please keep us updated on SUNP's status along with your expectations.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News